EGFR and non-small cell lung carcinoma: Moreover, the lysine reduction could enhance the cytostatic effect of osimertinib in EGFR-mutant NSCLC cells and it was connected with the regulation of the lysine catabolizing enzyme, α-aminoadipate aminotransferase by EGFR–AKT signaling [77].